AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16891136 — intervention group
Group type: EXPERIMENTAL
Intervention: levalbuterol 0.63 mg via nebulizer
Number of subjects: 262
Study 16891136 — intervention group
Group type: EXPERIMENTAL
Intervention: racemic albuterol 1.25 mg via nebulizer
Number of subjects: 262
Study 16891136 — intervention group
Group type: EXPERIMENTAL
Intervention: racemic albuterol 2.5 mg via nebulizer
Number of subjects: 262
Study 16891136 — intervention group
Group type: COMPARATOR
Intervention: (S)-albuterol presence
Number of subjects: 262
Study 15088306 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg (2.5 ml) hyaluronan (HA) in a phosphate buffered solution
Number of subjects: 240
Study 15088306 — intervention group
Group type: COMPARATOR
Intervention: Saline vehicle (2.5 ml vehicle containing only the buffer)
Number of subjects: 240
Study 15088306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular HA treatment
Number of subjects: 240
Study 11293751 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligation plus APC
Number of subjects: 60
Study 11293751 — intervention group
Group type: COMPARATOR
Intervention: Ligation alone
Number of subjects: 60
Study 9635603 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg three times a day)
Number of subjects: 24
Study 9635603 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (50 mg three times a day)
Number of subjects: 24
Study 9635603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8159153 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV)
Number of subjects: 7000
Study 3042126 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (15 mg/day)
Number of subjects: 30
Study 3042126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30744880 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 LCPUFA (722 mg/day DHA)
Number of subjects: 111
Study 30744880 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 IU/day)
Number of subjects: 111
Study 30744880 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 IU/day) + Omega-3 LCPUFA (722 mg/day DHA)
Number of subjects: 111
Study 30744880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 28097633 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized meropenem therapy based on a population PK/PD model
Number of subjects: 79
Study 28097633 — intervention group
Group type: COMPARATOR
Intervention: Standard meropenem regimen decided by the attending physician
Number of subjects: 79
Study 25496795 — intervention group
Group type: EXPERIMENTAL
Intervention: Wiggio (W) group
Number of subjects: 14
Study 25496795 — intervention group
Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 14
Study 24021179 — intervention group
Group type: EXPERIMENTAL
Intervention: Quatrix IOL
Number of subjects: 67
Study 24021179 — intervention group
Group type: COMPARATOR
Intervention: AR40e IOL
Number of subjects: 67
Study 21508849 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 106
Study 21508849 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 106
Study 17989918 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (AC)
Number of subjects: 40
Study 17989918 — intervention group
Group type: COMPARATOR
Intervention: Control acupuncture (controlAC)
Number of subjects: 40
Study 15175633 — intervention group
Group type: EXPERIMENTAL
Intervention: Sour milk fermented with Lactobacillus helveticus containing 2.4-2.7 mg of Ile-Pro-Pro and 2.4-2.7 mg of Val-Pro-Pro per 1.5 dl, taken daily.
Number of subjects: 60
Study 15175633 — intervention group
Group type: COMPARATOR
Intervention: Placebo (regular sour milk), taken daily.
Number of subjects: 60
Study 12538116 — intervention group
Group type: EXPERIMENTAL
Intervention: CorLink device for anastomosis between saphenous vein and ascending aorta
Number of subjects: 21
Study 12538116 — intervention group
Group type: COMPARATOR
Intervention: 6-0 running suture for central bypass anastomosis
Number of subjects: 21
Study 9719049 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH insulin (0.3 U/kg body wt per day)
Number of subjects: 23
Study 9719049 — intervention group
Group type: COMPARATOR
Intervention: Insulin infusion
Number of subjects: 23
Study 7654109 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 352
Study 7654109 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 352
Study 7654109 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 352
Study 7654109 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 352
Study 7654109 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 352
Study 7654109 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 352
Study 7654109 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem after hydrochlorothiazide failure
Number of subjects: 352
Study 7654109 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine after atenolol failure
Number of subjects: 352
Study 7654109 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin after captopril failure
Number of subjects: 352
Study 7654109 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem after clonidine failure
Number of subjects: 352
Study 7654109 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril after diltiazem failure
Number of subjects: 352
Study 7654109 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine after prazosin failure
Number of subjects: 352
Study 7654109 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (combined response rate)
Number of subjects: 352
Study 7654109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study 2655256 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg)
Number of subjects: 60
Study 2655256 — intervention group
Group type: COMPARATOR
Intervention: Metimazole (2.5 g)
Number of subjects: 60
Study 334611 — intervention group
Group type: EXPERIMENTAL
Intervention: Butacote (300 mg daily)
Number of subjects: 23
Study 334611 — intervention group
Group type: COMPARATOR
Intervention: fenclofenac (1200 mg daily)
Number of subjects: 23
Study 334611 — intervention group
Group type: EXPERIMENTAL
Intervention: Butacote
Number of subjects: 23
Study 334611 — intervention group
Group type: COMPARATOR
Intervention: Butacote and fenclofenac
Number of subjects: 23
Study 31920107 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 0
Study 31920107 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape juice
Number of subjects: 0
Study 31002638 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based lifestyle program
Number of subjects: 0
Study 31002638 — intervention group
Group type: COMPARATOR
Intervention: Control group (no program offered)
Number of subjects: 0
Study 31002638 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups pooled
Number of subjects: 0
Study 28187159 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE's Community Score Card (CSC) intervention
Number of subjects: 0
Study 28187159 — intervention group
Group type: EXPERIMENTAL
Intervention: Community- and provider-developed indicators
Number of subjects: 0
Study 25916220 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone 24 μg twice daily for 12 weeks
Number of subjects: 431
Study 25916220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study 21192244 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-Amodiaquine coformulated
Number of subjects: 120
Study 21192244 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-Amodiaquine copackaged
Number of subjects: 120
Study 21192244 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-Amodiaquine (both formulations)
Number of subjects: 120
Study 21609157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)‐based brief intervention and education program
Number of subjects: 62
Study 21609157 — intervention group
Group type: COMPARATOR
Intervention: Education program
Number of subjects: 62
Study 19456003 — intervention group
Group type: EXPERIMENTAL
Intervention: AGS (inflatable antigravity suit)
Number of subjects: 19
Study 19456003 — intervention group
Group type: EXPERIMENTAL
Intervention: Kentavr (non-inflatable compression garment)
Number of subjects: 19
Study 19456003 — intervention group
Group type: COMPARATOR
Intervention: Control group (hypovolemic subjects)
Number of subjects: 19
Study 19456003 — intervention group
Group type: EXPERIMENTAL
Intervention: AGS and Kentavr
Number of subjects: 19
Study 16716877 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 11352
Study 16716877 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 11352
Study 16716877 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone
Number of subjects: 11352
Study 15662995 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg
Number of subjects: 0
Study 15662995 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 800 mg
Number of subjects: 0
Study 15662995 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 1200 mg
Number of subjects: 0
Study 15662995 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 0
Study 11726841 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection therapy (epinephrine and polidocanol)
Number of subjects: 63
Study 11726841 — intervention group
Group type: COMPARATOR
Intervention: No endoscopic therapy (control group)
Number of subjects: 63
Study 9160197 — intervention group
Group type: COMPARATOR
Intervention: North Europe
Number of subjects: 2201
Study 9160197 — intervention group
Group type: COMPARATOR
Intervention: South Europe
Number of subjects: 2201
Study 9160197 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regions
Number of subjects: 2201
Study 8125425 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (ACE inhibitor)
Number of subjects: 6797
Study 3309199 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate (MTX) 15 mg
Number of subjects: 44
Study 3309199 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal methotrexate (MTX) 15 mg plus cytosine arabinoside (Ara-C) 50 mg/m2
Number of subjects: 44
Study 3309199 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs administered via Ommaya reservoir
Number of subjects: 44
Study 3309199 — intervention group
Group type: COMPARATOR
Intervention: Drugs administered via lumbar puncture
Number of subjects: 44
Study 3309199 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent radiotherapy to the CNS
Number of subjects: 44
Study 3309199 — intervention group
Group type: COMPARATOR
Intervention: No concurrent radiotherapy to the CNS
Number of subjects: 44
Study 3309199 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 44
Study 3309199 — intervention group
Group type: COMPARATOR
Intervention: Nonresponders
Number of subjects: 44
Study 31545914 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3 (100 nmol/L, 12 h)
Number of subjects: 30
Study 31545914 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 30
Study 29345161 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (6 mg/kg body weight, 60 min pretrial)
Number of subjects: 26
Study 26881934 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP 110≤SBP<120
Number of subjects: 97013
Study 26881934 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP 120≤SBP<130
Number of subjects: 97013
Study 26881934 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP 130≤SBP<140
Number of subjects: 97013
Study 26881934 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP 140≤SBP<150
Number of subjects: 97013
Study 26881934 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP 150≤SBP<160
Number of subjects: 97013
Study 26881934 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP 160≤SBP<170
Number of subjects: 97013
Study 26881934 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP 170≤SBP<180
Number of subjects: 97013
Study 26881934 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP ≥180
Number of subjects: 97013
Study 24045072 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquacel(®) Ag dressing
Number of subjects: 100
Study 24045072 — intervention group
Group type: COMPARATOR
Intervention: Acticoat™ dressing
Number of subjects: 100
Study 22435251 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 32
Study 22435251 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Snake Scope camera (FSSC)
Number of subjects: 32
Study 22435251 — intervention group
Group type: COMPARATOR
Intervention: Both methods (DL and FSSC)
Number of subjects: 32
Study 19878621 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples' Illness Communication Scale (CICS)
Number of subjects: 288
Study 18490931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod diet (3 x 150 g week(‐1))
Number of subjects: 324
Study 18490931 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon diet (3 x 150 g week(‐1))
Number of subjects: 324
Study 18490931 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (DHA/EPA capsules, no seafood)
Number of subjects: 324
Study 18490931 — intervention group
Group type: COMPARATOR
Intervention: Control (sunflower oil capsules, no seafood)
Number of subjects: 324
Study 15986036 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (GEM) alone
Number of subjects: 94
Study 15986036 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM) with continuous infusion 5-FU (CI 5-FU)
Number of subjects: 94
Study 12185157 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Number of subjects: 17
Study 12185157 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 17
Study 12185157 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation and levodopa combined
Number of subjects: 17
Study 12185157 — intervention group
Group type: COMPARATOR
Intervention: Off condition (no treatment)
Number of subjects: 17
Study 12185157 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Deep brain stimulation, Levodopa, both)
Number of subjects: 17
Study 9988393 — intervention group
Group type: EXPERIMENTAL
Intervention: Seminal oxidative stress measurement in infertile reversal patients
Number of subjects: 30
Study 9988393 — intervention group
Group type: EXPERIMENTAL
Intervention: Seminal oxidative stress measurement in all reversal patients
Number of subjects: 30
Study 9988393 — intervention group
Group type: EXPERIMENTAL
Intervention: ROS‐TAC score as a predictor of fertility
Number of subjects: 30
Study 9988393 — intervention group
Group type: COMPARATOR
Intervention: Total antioxidant capacity measurement
Number of subjects: 30
Study 7574193 — intervention group
Group type: EXPERIMENTAL
Intervention: Low blood pressure goal (target mean arterial pressure < or = 92 mm Hg for patients ≤ 60 years and < or = 98 mm Hg for patients ≥ 61 years)
Number of subjects: 840
Study 7574193 — intervention group
Group type: COMPARATOR
Intervention: Usual blood pressure goal (target mean arterial pressure < or = 107 mm Hg for patients ≤ 60 years and < or = 113 mm Hg for patients ≥ 61 years)
Number of subjects: 840
Study 7574193 — intervention group
Group type: EXPERIMENTAL
Intervention: Low blood pressure goal
Number of subjects: 840
Study 1689417 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg
Number of subjects: 8
Study 1689417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 359110 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 50 mg
Number of subjects: 920
Study 359110 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 75 to 150 mg
Number of subjects: 920
Study 359110 — intervention group
Group type: COMPARATOR
Intervention: No Meperidine (Control)
Number of subjects: 920
Study 30907180 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological counselling (PC) and Nutritional Counselling (NC)
Number of subjects: 40
Study 30907180 — intervention group
Group type: COMPARATOR
Intervention: Nutritional treatment (Control Group)
Number of subjects: 40
Study 31161927 — intervention group
Group type: EXPERIMENTAL
Intervention: Shilajit supplementation (125 or 250 mg bid)
Number of subjects: 0
Study 31161927 — intervention group
Group type: EXPERIMENTAL
Intervention: Shilajit supplementation (250 mg bid)
Number of subjects: 0
Study 31161927 — intervention group
Group type: EXPERIMENTAL
Intervention: Shilajit supplementation
Number of subjects: 0
Study 28550195 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 32
Study 28550195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 26081815 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib (an inhibitor of vascular endothelial growth factor receptors) combined with carboplatin-paclitaxel
Number of subjects: 296
Study 26081815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 23564425 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar incision
Number of subjects: 76
Study 23564425 — intervention group
Group type: COMPARATOR
Intervention: Dorsal incision
Number of subjects: 76
Study 21650085 — intervention group
Group type: EXPERIMENTAL
Intervention: LFM-A13
Number of subjects: 135
Study 21650085 — intervention group
Group type: EXPERIMENTAL
Intervention: LFM-A13 + Vincristine
Number of subjects: 135
Study 18777156 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 5
Study 18777156 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Number of subjects: 5
Study 16132055 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g per day of water-soluble fiber from oat bran
Number of subjects: 110
Study 16132055 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 14735366 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted infrared thermography
Number of subjects: 18
Study 14735366 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 18
Study 14735366 — intervention group
Group type: EXPERIMENTAL
Intervention: CRPS1 patients
Number of subjects: 18
Study 11762655 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticonvulsant medication
Number of subjects: 111
Study 11762655 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 111
Study 10960380 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mL of 1.5% (60‐mg dose) plain mepivacaine (Group 1)
Number of subjects: 60
Study 10960380 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mL of 2% (80‐mg dose) plain mepivacaine (Group 2)
Number of subjects: 60
Study 10960380 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of plain mepivacaine
Number of subjects: 60
Study 8985797 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-Care Rehabilitation Program (HCRP)
Number of subjects: 15
Study 8985797 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 1289359 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 234
Study 1289359 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin plus gentamicin
Number of subjects: 234
Study 6367533 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide
Number of subjects: 77
Study 6367533 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg domperidone
Number of subjects: 77
Study 6367533 — intervention group
Group type: COMPARATOR
Intervention: NaCl as placebo
Number of subjects: 77
Study 29290182 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Epidural Analgesia (Group E)
Number of subjects: 60
Study 29290182 — intervention group
Group type: COMPARATOR
Intervention: Single-Shot Femoral Nerve Block (Group F)
Number of subjects: 60
Study 27143676 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography angiography testing
Number of subjects: 10003
Study 27143676 — intervention group
Group type: COMPARATOR
Intervention: Functional testing
Number of subjects: 10003
Study 25113139 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational counseling intervention (4 individual sessions)
Number of subjects: 166
Study 25113139 — intervention group
Group type: COMPARATOR
Intervention: Control (usual lifestyle)
Number of subjects: 166
Study 25113139 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational counseling intervention
Number of subjects: 166
Study 21878804 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week nutritional supplementation
Number of subjects: 0
Study 21878804 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 20083428 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed high-frequency electromagnetic field (EMF) emitted by a mobile phone
Number of subjects: 10
Study 20083428 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 10
Study 17434095 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH), nadroparin calcium 3800 anti-factor Xa IU/0.4 mL twice daily for 10 days, then aspirin 80-300 mg once daily for 6 months
Number of subjects: 353
Study 17434095 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 160 mg daily for 10 days, then aspirin 80-300 mg once daily for 6 months
Number of subjects: 353
Study 17434095 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 353
Study 15685040 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with DDP (80 mg/m2 intravenously day 1 only) and VP-16 (80 mg/m2 intravenously days 1-3) every 3 weeks for 5 cycles without tamoxifen.
Number of subjects: 319
Study 15685040 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with DDP and VP-16 plus high-dose tamoxifen (80 mg orally twice per day for 5 days each cycle starting 1 day before DDP).
Number of subjects: 319
Study 11854640 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal misoprostol (200 microg initially, increased to 300 microg)
Number of subjects: 157
Study 11854640 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal misoprostol (50 microg initially, increased to 100 microg)
Number of subjects: 157
Study 11854640 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal misoprostol
Number of subjects: 157
Study 11854640 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal misoprostol
Number of subjects: 157